The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

The monoclonal antibody (mAb) helped maintain safe platelet levels for a prolonged period, reducing patient reliance on ...

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Results from the Phase III NEPTUNUS-1 (NCT05350072) and NEPTUNUS-2 (NCT05349214) trials demonstrated that ianalumab ...

Novartis today announced positive top-line results from its Phase III trials evaluating ianalumab (VAY736) in adults with ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Ianalumab is a fully human monoclonal antibody designed to deplete B cells via antibody-dependent cellular toxicity and inhibit BAFF-R-mediated signals of B cell function and survival.